Neumora revises stock option repricing to use closing price on May 28, 2025 annual meeting date

Neumora Therapeutics, Inc.

Originally repriced using Feb 13, 2025 closing price; revised on Apr 7, 2025 to use closing price on scheduled annual meeting date (May 28, 2025).
Repricing applies to eligible options held by board, named executive officers, and other service providers under 2023 and 2020 equity plans.
Reduced exercise price requires stockholder approval; options must be exercised on/after Aug 13, 2026 while service continues.
Except for the closing price date, all other terms of repriced options remain unchanged.
Annual stockholder meeting scheduled for May 28, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.